MX2025002312A - Terapias combinadas para el tratamiento de linfomas de celulas t con tolinapant, cedazuridina y decitabina - Google Patents
Terapias combinadas para el tratamiento de linfomas de celulas t con tolinapant, cedazuridina y decitabinaInfo
- Publication number
- MX2025002312A MX2025002312A MX2025002312A MX2025002312A MX2025002312A MX 2025002312 A MX2025002312 A MX 2025002312A MX 2025002312 A MX2025002312 A MX 2025002312A MX 2025002312 A MX2025002312 A MX 2025002312A MX 2025002312 A MX2025002312 A MX 2025002312A
- Authority
- MX
- Mexico
- Prior art keywords
- combination therapies
- tolinapant
- cedazuridine
- decitabine
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263374137P | 2022-08-31 | 2022-08-31 | |
| PCT/IB2022/060652 WO2024047394A1 (en) | 2022-08-31 | 2022-11-04 | Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025002312A true MX2025002312A (es) | 2025-04-02 |
Family
ID=84359488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025002312A MX2025002312A (es) | 2022-08-31 | 2025-02-26 | Terapias combinadas para el tratamiento de linfomas de celulas t con tolinapant, cedazuridina y decitabina |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240082286A1 (https=) |
| EP (1) | EP4580635A1 (https=) |
| JP (1) | JP2025529240A (https=) |
| KR (1) | KR20250053870A (https=) |
| AU (1) | AU2022476674A1 (https=) |
| CA (1) | CA3266274A1 (https=) |
| MX (1) | MX2025002312A (https=) |
| TW (1) | TW202410893A (https=) |
| WO (1) | WO2024047394A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122022015241B1 (pt) | 2013-12-20 | 2023-09-26 | Astex Therapeutics Limited | Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| BR122022015241B1 (pt) | 2013-12-20 | 2023-09-26 | Astex Therapeutics Limited | Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i) |
| US12239653B2 (en) * | 2020-02-25 | 2025-03-04 | Taiho Pharmaceutical Co., Ltd. | Combination decitabine and cedazuridine solid oral dosage forms |
-
2022
- 2022-11-04 EP EP22805975.4A patent/EP4580635A1/en active Pending
- 2022-11-04 TW TW111142283A patent/TW202410893A/zh unknown
- 2022-11-04 JP JP2025513127A patent/JP2025529240A/ja active Pending
- 2022-11-04 KR KR1020257007164A patent/KR20250053870A/ko active Pending
- 2022-11-04 CA CA3266274A patent/CA3266274A1/en active Pending
- 2022-11-04 WO PCT/IB2022/060652 patent/WO2024047394A1/en not_active Ceased
- 2022-11-04 AU AU2022476674A patent/AU2022476674A1/en active Pending
-
2023
- 2023-08-30 US US18/458,884 patent/US20240082286A1/en active Pending
-
2025
- 2025-02-26 MX MX2025002312A patent/MX2025002312A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202410893A (zh) | 2024-03-16 |
| US20240082286A1 (en) | 2024-03-14 |
| WO2024047394A1 (en) | 2024-03-07 |
| CA3266274A1 (en) | 2024-03-07 |
| JP2025529240A (ja) | 2025-09-04 |
| KR20250053870A (ko) | 2025-04-22 |
| AU2022476674A1 (en) | 2025-04-17 |
| EP4580635A1 (en) | 2025-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| EP4616902A3 (en) | Nerve stimulation for treating migraine and other headache conditions | |
| MX2025005315A (es) | Celulas t para usarse en el tratamiento de una enfermedad o afeccion | |
| WO2023009834A3 (en) | Methods of treating cancer | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| MX2023011856A (es) | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer. | |
| CA227900S (en) | Skin treatment equipment | |
| MX2022003193A (es) | Tratamiento de encefalopatia asociada al gen syngap1. | |
| PH12023552792A1 (en) | Combination therapies for the treatment of cancer | |
| PH12020551976A1 (en) | SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS | |
| MX2021009079A (es) | Metodos para tratar el mieloma multiple. | |
| MX2025002312A (es) | Terapias combinadas para el tratamiento de linfomas de celulas t con tolinapant, cedazuridina y decitabina | |
| NZ747910A (en) | Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells | |
| MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
| WO2021041539A3 (en) | Pyrido-indole analogues as gpx4 inhibitors | |
| MX2021004819A (es) | Composiciones y metodos para tratar lesiones cerebrales. | |
| MX2020011817A (es) | Metodos para tratar el linfoma. | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| MX2023006551A (es) | Tratamiento de las convulsiones refractarias. | |
| MX2024015041A (es) | Fitusiran para el tratamiento de la hemofilia a y b | |
| PH12022551008A1 (en) | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma | |
| WO2021041716A3 (en) | Therapeutic editing to treat cardiomyopathy | |
| MX2023006651A (es) | Tratamiento de la hemofilia con fitusirán. | |
| PH12022552489A1 (en) | V delta1+ t cells for the treatment of myeloid malignancies | |
| EP4623999A3 (en) | Sotorasib for use in the treatment of cancer |